Use of leflunomide to control and reverse chronic allograft rejection
US5624946A · kind A · utility
Inventor
Key dates
| Filing date | Jul 5, 1994 |
| Grant date | Apr 29, 1997 |
| Priority date | — |
| Expiry date | Jul 5, 2014 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/13
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of controlling or reversing chronic rejection of allografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, rapamycin and corticosteroids. The invention also relates to methods of preventing or controlling acute and chronic rejection of xenografts in a transplantation patient by administering leflunomide product alone, or in combination with one or more immunosuppressive agents selected from the group consisting of Cyclosporine A, FK506, rapamycin and corticosteroids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.